Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has resubmitted its New...
An analyst from H.C. Wainwright upgraded Akebia Ther (NASDAQ: AKBA) from 'neutral' to 'buy' with a price target of $3.75. Prior to this rating, Akebia Ther had 1 buy ratings, 1 hold...
Investing.com - Akebia Ther (NASDAQ: AKBA) reported second quarter EPS of $-0.060, $0.03 worse than the analyst estimate of $-0.030. Revenue for the quarter came in at $56.4M versus the...
Akebia Therapeutics (NASDAQ:AKBA)®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the...
Akebia Therapeutics (NASDAQ:AKBA)®, Inc. (Nasdaq: AKBA) today announced that Akebia completed an End of Dispute Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss...
Akebia Therapeutics (NASDAQ:AKBA)®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced topline...
Akebia Therapeutics (NASDAQ:AKBA)®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Ellen...
An analyst from Piper Sandler upgraded Akebia Ther (NASDAQ: AKBA) from 'neutral' to 'overweight' with a price target of $4.00 from a prior price target of $2.00. Prior to this rating,...
Akebia Therapeutics (NASDAQ:AKBA)®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the...
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced an agreement with MEDICE...
Akebia Therapeutics (NASDAQ:AKBA)®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has...
Akebia Therapeutics (NASDAQ:AKBA)®, Inc. (Nasdaq: AKBA) today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing...
Investing.com - Akebia Ther (NASDAQ: AKBA) reported first quarter EPS of $-0.140, better than the analyst estimate of $-0.150. Revenue for the quarter came in at $40.13M versus the consensus...
A H.C. Wainwright analyst maintained Akebia Ther (NASDAQ: AKBA) at Neutral and a price target of $2.00 from a prior price target of $1.25. Prior to this rating, Akebia Ther had 0 buy...
Akebia Therapeutics (NASDAQ:AKBA)®, Inc. (Nasdaq: AKBA) today announced that the European Commission (EC) has granted marketing authorisation for Vafseo™ (vadadustat), an oral...
Akebia Therapeutics (NASDAQ:AKBA), Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will...
Akebia Therapeutics (NASDAQ:AKBA)®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced positive...
Akebia Therapeutics (NASDAQ:AKBA)®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the...
Investing.com - Akebia Ther (NASDAQ: AKBA) reported first quarter EPS of $-0.040, $0.14 better than the analyst estimate of $-0.184. Revenue for the quarter came in at $55.18M versus the...
Akebia Therapeutics (NASDAQ:AKBA)®, Inc. (AKBA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive...
Akebia Therapeutics (NASDAQ:AKBA)®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the...
Pre-Open Stock Movers:Akebia Therapeutics, Inc. (Nasdaq: NASDAQ:AKBA) 37% HIGHER; executed an agreement to terminate the U.S. and ex-U.S. vadadustat Collaboration and License Agreements with...
Akebia Therapeutics (NASDAQ:AKBA) reported Q1 EPS of ($0.35), $0.06 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $61.7 million versus the consensus estimate...
Investing.com – U.S. equities were lower at the close on Wednesday, as losses in the Consumer Services, Technology and Financials sectors propelled shares lower. At the close in NYSE, the...
Investing.com – U.S. equities were lower at the close on Thursday, as losses in the Technology, Basic Materials and Consumer Goods sectors propelled shares lower. At the close in NYSE, the...
Investing.com – U.S. equities were lower at the close on Thursday, as losses in the Technology, Consumer Services and Consumer Goods sectors propelled shares lower. At the close in NYSE,...
By Christiana Sciaudone Investing.com -- Akebia Therapeutics (NASDAQ:AKBA) plummeted 73% to $2.70 after saying its experimental drug failed to meet the main safety goal in a late-stage...
* Home Depot (NYSE:HD) top stock on Dow and S&P after profit beat* Pfizer down after Citi cuts to "sell"* Dollar hits 6-month low; gold up* Dow down 0.07 pct, S&P down...
* Home Depot (NYSE:HD) top stock on Dow after profit beat * Pfizer down after Citi cuts to "sell" * Indexes up: Dow 0.18 pct, S&P 0.09 pct, Nasdaq 0.14 pct (Updates to open) By...
* Home Depot (NYSE:HD) rises on profit beat * S&P, Nasdaq closed at record levels on Monday * Futures up: Dow 33 pts, S&P 1.75 pt, Nasdaq 6.5 pts (Adds details, comments, updates...
* Futures up: Dow 27 pts, S&P 1 pt, Nasdaq 4.5 pts By Yashaswini Swamynathan May 16 (Reuters) - U.S. stock index futures were little changed on Tuesday as investors paused for a...
Investing.com – U.S. equities were lower at the close on Wednesday, as losses in the Consumer Goods, Oil & Gas and Basic Materials sectors propelled shares lower. At the close in NYSE, the...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
